Lennox-Gastaut Syndrome Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Lennox-Gastaut Syndrome remains an active clinical development field. The field is increasingly separating symptomatic benefit from disease modification, while enrichment, digital measures and fluid or imaging biomarkers reshape trial design. The PatSnap evidence set used here contains 32 matched trial records and 76 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07568860 | Intervention not normalized | Not Applicable; Not yet recruiting | University of Minnesota | Geography not listed | Change in total tonic motor seizures between baseline (assessed by Caregiver reported seizures) and adaptive stimulation double-blinded study phase (assessed by Medtronic Percept PC system timeline data). (Total tonic seizure count at baseline are for the 3 months prior to invasive…); Change in total tonic motor seizures between baseline (assessed by Caregiver reported seizures) and adaptive stimulation double-blinded study phase (assessed by seizure detection watch data). (Total tonic seizure count at baseline are for the 3 months prior to invasive…) | 2030-09-30 |
| CTR20261254 | Compound Caraway Enteric Liquid Capsule | Phase 3; 进行中 （招募中） | Tianjin Institute of Pharmaceutical Research Co., Ltd.; Hebei Aierhaitai Pharmacy Co. Ltd. | China | (用药4周后) | Timing not listed |
| NCT07225231 | Intervention not normalized | Not Applicable; Not yet recruiting | Byteflies NV | Geography not listed | Physician confidence in treatment decision-making using RPM data (At end of first RPM period (2 weeks after treatment start), at end of second…) | 2026-12-31 |
| ACTRN12625000735459 | Intervention not normalized | Not Applicable; Not yet recruiting | University of Melbourne | Australia | Primary endpoint not listed | Timing not listed |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2) (Phase 3): the indexed record reports -; -; Number of Participants With At Least One Treatment Emergent Adverse Event (TEAE) = 293 Participants.
- Cannabidiol Efficacy in Patients with Lennox-Gastaut Syndrome with Developmental and Epileptic Encephalopathy-associated Genetic Variants: A Subgroup Analysis (Not Applicable): the indexed record reports TEAE = 90.9 %; TEAE = 90.3 %.
- A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of Soticlestat (TAK-935) as Adjunctive Therapy in Subjects With Developmental Epileptic Encephalopathies Including Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome (ENDYMION 1) (Phase 2): the indexed record reports -; -; -.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Compound Caraway Enteric Liquid Capsule (Phase 3). Company & Deal Intelligence records identify sponsor context for University of Minnesota, Tianjin Institute of Pharmaceutical Research Co., Ltd., Hebei Aierhaitai Pharmacy Co. Ltd., Byteflies NV, University of Melbourne. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Validated biomarkers that bridge biological activity to meaningful function.
- Longer follow-up that distinguishes transient symptom change from altered disease trajectory.
- Decentralized and digital measures that reduce noise without increasing patient burden.
- Trials designed around genetically or biologically defined subgroups.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Lennox-Gastaut Syndrome has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
